Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning, Myocardial | 8 | 2005 | 23 | 0.890 |
Why?
|
| Myocardial Ischemia | 5 | 2007 | 121 | 0.860 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2007 | 29 | 0.720 |
Why?
|
| Myocardium | 5 | 2007 | 302 | 0.610 |
Why?
|
| Insecticides | 3 | 2006 | 45 | 0.610 |
Why?
|
| Protein Precursors | 2 | 2007 | 85 | 0.520 |
Why?
|
| Receptors, Opioid | 2 | 2007 | 15 | 0.450 |
Why?
|
| Diazepam | 2 | 2006 | 10 | 0.440 |
Why?
|
| Dichlorvos | 2 | 2006 | 15 | 0.430 |
Why?
|
| Rats | 13 | 2007 | 2002 | 0.390 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.390 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 11 | 0.380 |
Why?
|
| Jejunum | 2 | 2002 | 15 | 0.370 |
Why?
|
| Fluorocarbons | 4 | 2002 | 54 | 0.370 |
Why?
|
| Liquid Ventilation | 2 | 2002 | 4 | 0.350 |
Why?
|
| Rabbits | 8 | 2006 | 342 | 0.340 |
Why?
|
| Hypothermia, Induced | 2 | 2001 | 48 | 0.330 |
Why?
|
| Patient Readmission | 2 | 2026 | 452 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 807 | 0.320 |
Why?
|
| Ischemia | 2 | 2002 | 203 | 0.320 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2002 | 27 | 0.310 |
Why?
|
| Animals | 27 | 2020 | 21467 | 0.300 |
Why?
|
| Management Quality Circles | 1 | 2009 | 2 | 0.300 |
Why?
|
| Organizational Case Studies | 1 | 2009 | 41 | 0.290 |
Why?
|
| Random Allocation | 6 | 2006 | 200 | 0.290 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.290 |
Why?
|
| Enkephalin, Methionine | 2 | 2006 | 9 | 0.290 |
Why?
|
| Rats, Wistar | 8 | 2003 | 184 | 0.280 |
Why?
|
| Transitional Care | 2 | 2026 | 32 | 0.280 |
Why?
|
| Total Quality Management | 1 | 2008 | 56 | 0.280 |
Why?
|
| Blood Transfusion | 2 | 1999 | 167 | 0.280 |
Why?
|
| Emergency Service, Hospital | 4 | 2026 | 1163 | 0.270 |
Why?
|
| Enkephalins | 1 | 2007 | 20 | 0.270 |
Why?
|
| Opioid Peptides | 1 | 2007 | 4 | 0.270 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 98 | 0.270 |
Why?
|
| Naloxone | 3 | 2004 | 53 | 0.260 |
Why?
|
| Physical Exertion | 1 | 2007 | 81 | 0.260 |
Why?
|
| Heart | 4 | 2007 | 298 | 0.260 |
Why?
|
| Trauma Centers | 1 | 2008 | 130 | 0.260 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 24 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2327 | 0.240 |
Why?
|
| Xylazine | 1 | 2006 | 5 | 0.240 |
Why?
|
| Antidotes | 1 | 2006 | 15 | 0.240 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 54 | 0.240 |
Why?
|
| Mobile Health Units | 1 | 2026 | 20 | 0.230 |
Why?
|
| Morphine | 1 | 2006 | 61 | 0.230 |
Why?
|
| Ketamine | 1 | 2006 | 39 | 0.230 |
Why?
|
| Hypothermia | 2 | 2001 | 15 | 0.210 |
Why?
|
| Narcotics | 1 | 2004 | 57 | 0.210 |
Why?
|
| Carotid Arteries | 2 | 2001 | 64 | 0.210 |
Why?
|
| Apnea | 1 | 2004 | 33 | 0.210 |
Why?
|
| Patient Discharge | 2 | 2026 | 521 | 0.200 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 797 | 0.200 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.200 |
Why?
|
| Tobramycin | 1 | 2003 | 6 | 0.200 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 33 | 0.200 |
Why?
|
| In Vitro Techniques | 5 | 2002 | 491 | 0.200 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2026 | 142 | 0.200 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 25 | 0.200 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.200 |
Why?
|
| Neutron Activation Analysis | 1 | 2003 | 3 | 0.190 |
Why?
|
| Ventricular Fibrillation | 2 | 2001 | 108 | 0.190 |
Why?
|
| Iohexol | 1 | 2003 | 18 | 0.190 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 34 | 0.190 |
Why?
|
| Organophosphate Poisoning | 1 | 2002 | 14 | 0.190 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 91 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 57 | 0.190 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 2002 | 2 | 0.180 |
Why?
|
| Receptors, Opioid, delta | 1 | 2002 | 5 | 0.180 |
Why?
|
| Potassium Channels | 1 | 2002 | 55 | 0.180 |
Why?
|
| Vaccines | 1 | 2023 | 97 | 0.180 |
Why?
|
| Swine | 4 | 2007 | 397 | 0.180 |
Why?
|
| Arm Injuries | 1 | 2001 | 12 | 0.180 |
Why?
|
| Leg Injuries | 1 | 2001 | 16 | 0.180 |
Why?
|
| Reperfusion Injury | 1 | 2002 | 57 | 0.180 |
Why?
|
| Myocardial Reperfusion | 4 | 2006 | 23 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 154 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 626 | 0.170 |
Why?
|
| Ventricular Function, Left | 2 | 2000 | 284 | 0.170 |
Why?
|
| Rewarming | 1 | 2001 | 6 | 0.170 |
Why?
|
| Resuscitation | 1 | 2001 | 67 | 0.170 |
Why?
|
| Hemostasis | 1 | 2020 | 19 | 0.160 |
Why?
|
| Coronary Vessels | 2 | 2009 | 125 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 33 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2001 | 344 | 0.160 |
Why?
|
| Drug Costs | 1 | 2020 | 55 | 0.160 |
Why?
|
| Femoral Artery | 1 | 2001 | 104 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2021 | 266 | 0.150 |
Why?
|
| Ischemic Preconditioning | 1 | 1999 | 8 | 0.150 |
Why?
|
| Male | 18 | 2026 | 31295 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2026 | 3329 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2020 | 204 | 0.150 |
Why?
|
| Norepinephrine | 1 | 1999 | 106 | 0.150 |
Why?
|
| Narcotic Antagonists | 3 | 2007 | 133 | 0.150 |
Why?
|
| Adenosine | 1 | 1999 | 79 | 0.150 |
Why?
|
| Myocardial Infarction | 3 | 2001 | 921 | 0.150 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 76 | 0.150 |
Why?
|
| Pain | 1 | 2001 | 400 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 858 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 154 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 41 | 0.130 |
Why?
|
| Respiration, Artificial | 2 | 1999 | 300 | 0.120 |
Why?
|
| Hemodynamics | 3 | 2001 | 252 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 442 | 0.110 |
Why?
|
| Humans | 17 | 2026 | 65650 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 1172 | 0.110 |
Why?
|
| Muscle, Smooth | 2 | 2007 | 135 | 0.110 |
Why?
|
| Frail Elderly | 2 | 2026 | 115 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 714 | 0.100 |
Why?
|
| Brain | 2 | 2003 | 1625 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2026 | 5656 | 0.090 |
Why?
|
| Perfusion | 3 | 2000 | 76 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1581 | 0.090 |
Why?
|
| Body Temperature | 2 | 2001 | 46 | 0.080 |
Why?
|
| Muscle Contraction | 2 | 2002 | 209 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2001 | 606 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 11 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 240 | 0.070 |
Why?
|
| Time Factors | 3 | 2009 | 3777 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 105 | 0.070 |
Why?
|
| Hospitals, Community | 1 | 2009 | 73 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2008 | 24 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2009 | 85 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 37 | 0.070 |
Why?
|
| Aged | 5 | 2026 | 15089 | 0.070 |
Why?
|
| Hospitals, Rural | 1 | 2008 | 17 | 0.070 |
Why?
|
| Seasons | 2 | 2020 | 140 | 0.070 |
Why?
|
| Subcutaneous Fat | 1 | 2009 | 50 | 0.070 |
Why?
|
| Health Plan Implementation | 1 | 2008 | 40 | 0.070 |
Why?
|
| Poisoning | 2 | 2006 | 27 | 0.070 |
Why?
|
| Adipogenesis | 1 | 2009 | 81 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 181 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 179 | 0.070 |
Why?
|
| Female | 8 | 2026 | 34309 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 100 | 0.070 |
Why?
|
| Kidney | 2 | 2007 | 458 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 691 | 0.070 |
Why?
|
| Models, Animal | 2 | 2009 | 242 | 0.060 |
Why?
|
| Aging | 2 | 2005 | 775 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 240 | 0.060 |
Why?
|
| Naltrexone | 1 | 2007 | 91 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 449 | 0.060 |
Why?
|
| United States | 4 | 2021 | 8166 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 542 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 611 | 0.060 |
Why?
|
| Adipocytes | 1 | 2009 | 275 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 72 | 0.060 |
Why?
|
| Intestines | 1 | 2007 | 184 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1403 | 0.060 |
Why?
|
| Cystitis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 17 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 328 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 253 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 56 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 828 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 42 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 60 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2154 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 97 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2639 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2005 | 158 | 0.050 |
Why?
|
| Gene Expression | 1 | 2007 | 855 | 0.050 |
Why?
|
| Allied Health Personnel | 1 | 2024 | 25 | 0.050 |
Why?
|
| Middle Aged | 4 | 2020 | 18439 | 0.050 |
Why?
|
| Inflammation | 2 | 2009 | 1195 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2023 | 8 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 10 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3501 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2026 | 498 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2003 | 28 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 29 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 59 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Xenon Isotopes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 32 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 60 | 0.050 |
Why?
|
| Iodine | 1 | 2003 | 21 | 0.050 |
Why?
|
| Glyburide | 1 | 2002 | 9 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mesentery | 1 | 2002 | 17 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2002 | 16 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 121 | 0.050 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2002 | 3 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1100 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 23 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 788 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2024 | 593 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 225 | 0.040 |
Why?
|
| Enkephalin, Leucine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 63 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 213 | 0.040 |
Why?
|
| Epinephrine | 1 | 2001 | 46 | 0.040 |
Why?
|
| Phenylpropanolamine | 1 | 2001 | 1 | 0.040 |
Why?
|
| Phentolamine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Hypoxia | 1 | 2002 | 121 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 372 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 17 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 21 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 15 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2006 | 717 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1026 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 388 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 15 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 57 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 197 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 579 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 31 | 0.040 |
Why?
|
| Body Weight | 1 | 2001 | 377 | 0.040 |
Why?
|
| Heart Rate | 1 | 2001 | 334 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1999 | 55 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 376 | 0.040 |
Why?
|
| Kerosene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Glucose | 1 | 2002 | 478 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 177 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 1999 | 83 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2001 | 267 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2001 | 535 | 0.040 |
Why?
|
| Penicillin G | 1 | 1998 | 5 | 0.030 |
Why?
|
| Adolescent | 3 | 2006 | 6350 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2001 | 420 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 436 | 0.030 |
Why?
|
| Mice | 2 | 2009 | 11174 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1567 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1592 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1573 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5820 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6948 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2005 | 58 | 0.020 |
Why?
|
| Triage | 1 | 2013 | 137 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 200 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1437 | 0.020 |
Why?
|
| Adult | 2 | 2013 | 17511 | 0.020 |
Why?
|
| Infant | 2 | 2006 | 1711 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1116 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 2076 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 12 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 14 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 23 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 61 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 37 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 96 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 80 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 77 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 126 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 323 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 162 | 0.020 |
Why?
|
| Child | 2 | 2006 | 4634 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2005 | 9 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 1235 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2193 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 289 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 663 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 371 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 318 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 963 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1634 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 47 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 88 | 0.010 |
Why?
|
| Longevity | 1 | 2001 | 119 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 148 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1999 | 160 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1999 | 197 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 3164 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 1715 | 0.010 |
Why?
|